OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Diabetes & Endocrinology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Paisan Ruamviboonsuk: saving sight in Thailand	945
Vitamin D supplementation and mortality	849
Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY	567
Madelung's disease in a rare 14th century Franco-Flemish woolen tapestry	515
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	493
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	407
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study – Authors' reply	399
South Africa to produce insulin for Africa in 2024	388
Correction to Lancet Diabetes Endocrinol 2023; 11: 942–54	364
Correction to Lancet Diabetes Endocrinol 2025; 13: 221–62	359
Prediabetes: much more than just a risk factor	356
Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study	339
Protein-binding therapy: a new approach to lower cholesterol	336
Management of thyroid nodules	309
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial	305
Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer	291
Ashley Grossman: finding a calling in neuroendocrinology	260
Mark Atkinson: bringing two worlds together	240
Vitamin D to prevent acute respiratory infections	238
Fetal growth patterns as early markers of fetal programming	234
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	191
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis	188
People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action	187
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	186
Implications of technology guidelines for low-income and middle-income countries	181

Diabetes and the WHO Model List of Essential Medicines	181
The human factor	172
Dissection of type 2 diabetes: a genetic perspective	172
Insulin for all: a hope yet to be realised	163
May Ng: a lifetime commitment to children	160
Tackling childhood obesity in low-socioeconomic status communities: what is the next step?	152
A framework for improving diabetes care in humanitarian emergencies	152
New metrics to support diabetes education and advocacy	149
Data processing in the DMagic cluster randomised controlled trial	148
Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study	129
Estimating the total incidence of type 1 diabetes in children and adolescents aged 0–19 years from 1990 to 2050: a global simulation-based analysis	125
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records	124
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	124
Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study	123
Challenges in implementing nationwide epidemiological studies on metabolic non-communicable diseases in low-income and middle-income countries	121
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial	121
Global diabetes incidence trends in young adults	120
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	114
Association of age with gaps in diabetes-related care and hospitalisations from childhood to young adulthood in Quebec, Canada: a cohort study	113
Semaglutide for obesity: four STEPs forward, but more to come	112
The growing global burden of thyroid cancer overdiagnosis	112
Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme	111
Diabetes and the WHO Model List of Essential Medicines	108
Big babies, small babies: metformin exposure in pregnancy	107
Iodine deficiency in Europe: vigilance and action required	104
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study	101
Milestone achievement for global access to blood glucose meters and test strips	100
Reducing sodium intake: step-by-step targets yield success	95
Thought for food: a Cushing's syndrome enigma explained	94
What's preventing us from curbing the obesity crisis?	94
Newer antidiabetic agents: at what price will they be cost effective?	93
The growing clinical effect of SGLT2 inhibitors	90
Progress in diabetes prevention or epidemiology—or both, or neither?	90
Mendelian randomisation and vitamin D: the importance of model assumptions	90
Targeting RET-mutated thyroid and lung cancer in the personalised medicine era	87
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes – Authors' reply	85
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	82
Banning diabetes blanket bans	82
Anand Hardikar: a scientific nomad searching for the truth	82
Hot topics on insulin access: the issue of thermostability	82
Gender disparities in publishing: from words to actions	82
The food system: hunger for change	81
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	78
The effect of monthly vitamin D supplementation on fractures: a tertiary outcome from the population-based, double-blind, randomised, placebo-controlled D-Health trial	78
The relevance of T3 in the management of hypothyroidism	78
What's in a decade?	77
GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs	74
Call for prospective studies of continuous glucose monitoring to define the glycaemic response to bariatric surgery	74
A compass for navigating the perils of hypertriglyceridaemia	73
Better testing and labelling of drugs for people with obesity	68

GLP-1 analogue therapy for obesity in people from Asia	65
Evaluation of a type 2 diabetes remission programme	63
Food additive emulsifiers and risk of type 2 diabetes	63
Evaluation of a type 2 diabetes remission programme – Authors' reply	62
Setmelanotide for the treatment of severe early-childhood genetic obesity	61
Tirzepatide adds hepatoprotection to its armoury	60
Childhood cancer survival: a gap in need of closing	59
Direct-to-consumer services: improving access to care for people with diabetes and obesity	59
Singapore's “War on Diabetes”	58
World Health Assembly ratifies first global diabetes targets	58
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial	56
SGLT2 inhibitors in clinical practice	56
Metabolic non-communicable diseases in India: time to act	56
Setmelanotide: new promise for the treatment of hypothalamic obesity?	56
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	56
Measuring serum testosterone in women	53
Adrenal myelolipomas	52
Obesity in the USA: diet and lifestyle key to prevention	49
Sleep: a neglected public health issue	49
Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study	49
National UK guidelines for the management of paediatric craniopharyngioma	49
An anti-PCSK9 pill a day to keep cholesterol away: next steps?	49
Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2–20 years) with type 1 diabetes: a population-based study	49
Correction to Lancet Diabetes Endocrinol 2023; 11: 785–87	48
Correction to Lancet Diabetes Endocrinol 2021; 9: 743–54	47
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	46
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	46
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	45
Correction to Lancet Diabetes Endocrinol 2022; 10: 58–74	44
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled	44
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis	44
Adrenocortical carcinoma: a practical guide for clinicians	44
Disease modifying therapies in diabetes and endocrinology	44
Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study	43
Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism	43
Osteoporosis in men	42
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials	41
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study	41
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study	40
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	40
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	40
Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials	40
Osteopenia: a key target for fracture prevention	39
Current insights and emerging trends in early-onset type 2 diabetes	39
Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement	39
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK	39
Tight versus liberal blood-glucose control in the intensive care unit: special considerations for patients with diabetes	39
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	38
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial	37
A new threat to obesity: vanity sizing	37
A community-based, multi-level, multi-setting, multi-component intervention to reduce weight gain among low socioeconomic status Latinx children with overweight or obesity: The Stanford GOALS randomis	37
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes	36
Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study	36
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	36
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, dou	36
Obesity in people living with type 1 diabetes	35
Impact of BMI on COVID-19 vaccine effectiveness	35
Sex steroids and the female brain across the lifespan: insights into risk of depression and Alzheimer's disease	35
The potential role for artificial intelligence in fracture risk prediction	35
Nutritional intake and bone health	35
Comparative effectiveness research in bariatric surgery and the need for complementary study designs	34
Consensus on diagnosis and management of Cushing's disease: a guideline update	34
Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study	34
Youth-onset type 2 diabetes among First Nations young people in northern Australia: a retrospective, cross-sectional study	34
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	33
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	33
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)	33
Gestational diabetes in Australia: navigating a tsunami	33
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	33
Dulaglutide for erectile dysfunction in type 2 diabetes	33
Stigma in type 1 diabetes: a global problem	32
Implementing digital systems in diabetes care in low-income and middle-income countries: successes and challenges	32
Diabetes and the WHO Model List of Essential Medicines	32
Nutrition-related health taxes: setting expectations	32
The uncomfortable truth about kidney disease in type 1 diabetes	31
Adverse childhood experiences in diabetes care	31
Challenges in the treatment of young people with type 2 diabetes	30
Jennifer Manne-Goehler: at the crossroads of pandemics	30
Lorenz Hofbauer: connecting the unexpected	29
Sylvia Kehlenbrink: facing the extremes	28

Principles for virtual health care to deliver real equity in diabetes	28
National registries as a catalyst to development of diabetes care in low-income and middle-income countries	28
Scientific medical conferences can be easily modified to improve female inclusion: a prospective study	27
Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study	26
Impact of the COVID-19 pandemic on transgender and gender diverse health care	26
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	26
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial	26
Precision medicine of obesity as an integral part of type 2 diabetes management – past, present, and future	25
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	25
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	24
Glycaemic index as part of the diabetes prevention strategy	24
Prioritising COVID-19 over everything: the unintended harm	24
Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study	24
Perceptions of alternative methods of insulin storage: an ethical dilemma	24
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	24
The TRAVERSE trial: cardiovascular safety of testosterone therapy for older men	22
The double burden of poor diets	22
Black oesophagus in an adolescent with type 2 diabetes	22
Out on a limb: living with diabetes in the Philippines during the pandemic	22
Correction to Lancet Diabetes Endocrinol 2025. Published online February 17. https://doi.org/10.1016/S2213-8587(24)00372-3	21
Trends in thyroid cancer incidence and overdiagnosis in the USA	21
Improving health equity through data collection	21
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	21
Trends in incidence, metastasis, and mortality from thyroid cancer in the USA from 1975 to 2019: a population-based study of age, period, and cohort effects	21
Youth gender services: a new model for regional care	20
Silver Bahendeka: the obligation to hope	20
Jonathan Valabhji: from clinical practice to policy making and back	20
COP27 Climate Change Conference: urgent action needed for Africa and the world	20
Biodiversity and its double-edged role in the pathogenesis of type 1 diabetes	20
Dianna Magliano: at the forefront of change	20
Global thyroid estimates in 2020	20
Rising diabetes diagnosis in long COVID	20
Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France	20
Metabolic non-communicable diseases in India: time to act – Authors' reply	19
Type 1 diabetes: heterogeneity in heritability	19
Can non-equilibrium thermodynamics explain skeletal muscle insulin resistance due to low mitochondrial content?	19
The role of nurses in diabetes care: challenges and opportunities	19
Iodine status in Iran: from deficient to replete	19
Promising treatment options with tirzepatide for Japanese individuals with obesity disease	19
Type 2 diabetes in familial hypercholesterolaemia: another look at traditional risk factors	19
Association between BMI and COVID-19 on hospital budgets	18
Maria Fleseriu: driving excellence in pituitary care	18
Food additive emulsifiers: a new risk factor for type 2 diabetes?	18
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	17
Lebanon: insulin out of reach after subsidies lifted	17
Childhood obesity: a growing pandemic	17
Risk of new-onset diabetes with high-intensity statin use	17
The changing character of diabetes complications	17
Achieving replicable subphenotypes of adult-onset diabetes	17
Prediabetes remission in people with obesity	16
There is no magic bullet for obesity	15
Food additive emulsifiers and risk of type 2 diabetes – Authors' reply	15
Environmental chemical obesogens, what can we do?	15
Correction to Lancet Diabetes Endocrinol 2024; published online July 22. https://doi.org/10.1016/S2213-8587(24)00163-3	15
Sex differences in familial hypercholesterolaemia	15